Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O60704
UPID:
TPST2_HUMAN
Alternative names:
Tyrosylprotein sulfotransferase 2
Alternative UPACC:
O60704; B3KQA7; Q6FI98; Q9H0V4
Background:
Protein-tyrosine sulfotransferase 2, alternatively known as Tyrosylprotein sulfotransferase 2, plays a crucial role in post-translational modifications by catalyzing the O-sulfation of tyrosine residues within acidic motifs of polypeptides. This process utilizes 3'-phosphoadenylyl sulfate (PAPS) as a cosubstrate, highlighting its significance in protein function and signaling pathways.
Therapeutic significance:
Understanding the role of Protein-tyrosine sulfotransferase 2 could open doors to potential therapeutic strategies. Its involvement in critical post-translational modifications suggests its potential as a target in diseases where these processes are dysregulated.